| Drug Name | Sutent (Sunitinib) |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Oncology
|
| Risk |
Association of Sutent®(Sunitinib) with Stevens-Johnson Syndrome(SJS) and Toxic Epidermal Necrolysis(TEN) |
| Dear Healthcare provider letter DHPC |
|